Glycomimetics Inc., of Rockville, Md., said the first of two patient cohorts in its phase II acute myeloid leukemia (AML) trial of GMI-1271 completed enrollment. The cohort comprises 25 patients, 60 and older, with newly diagnosed AML. It's designed to evaluate the potential of GMI-1271, an E-selectin antagonist drug candidate, in combination with chemotherapy, as a treatment for patients with both newly diagnosed and relapsed/refractory AML. Enrollment in the study's second arm is expected to complete in the middle of this year. The two arms combined will enroll a total of about 90 patients.